Latest News Archive

Please select Category, Year, and then Month to display items

Donovan Wright: ‘Teaching South African Sign Language is my great passion’

23 September 2022 | Story Rulanzen Martin | Photo Rulanzen Martin

Donovan Wright recently joined the University of the Free State (UFS) as a lecturer in the Department of South African Sign Language (SASL) and Deaf Studies. As a passionate young academic, Wright ‘found his love’ for SASL during his undergraduate years at the University of the Witwatersrand (Wits).

In 2016, for the fulfilment of his master’s degree at Wits, Wright completed a thesis titled ‘A preliminary description of South African Sign Language syntax’. He is currently pursuing his PhD at Wits, and his research interests lie in the linguistics of SASL, which became his focus during his postgraduate studies. In his PhD research he focuses on (particular) constructions within SASL and how to best describe and analyse them. “I chose to use an approach to language and grammar not tied to how we perceive and understand spoken languages,” he says.

‘Teaching SASL is my great passion’

His appointment as a SASL lecturer at the UFS is a fulfilment of his passion for teaching. “Sign languages are commonly misunderstood and thought to be pantomime or gesture,” he says. “These common misconceptions are the first topic we tackle – whether by linguistic or social argument.” As a SASL linguistics lecturer he says it’s this aspect of the modules that is so rewarding, especially “seeing students realise something new about a sign they already know and have been using. Learning about language while learning a language has its benefits.”

Empowering students is about access

Wright says access to education is a fundamental right for every student, and that empowering Deaf scholars will ultimately improve how Deaf students access information at universities and elsewhere. “While many students attend university and access their education in a language that is not their mother tongue, Deaf students using SASL are additionally learning across modalities.”

September is designated as Deaf Awareness Month, with one important aim being to highlight and improve sign language education. The Department of South African Sign Language and Deaf Studies has planned numerous events and initiatives during this month, which will raise awareness and provide community education by visiting schools.

“The next step is ensuring an environment in which Deaf students who choose to pursue a career in academia are not hindered. Our Deaf students are our future Deaf academics,” Wright says.

• Members of the Department of South African Sign Language and Deaf Studies will, among other planned events, provide community interpreting services and visit schools in surrounding areas. This year the department is launching a university ‘Deaf Space’ where students, staff, or anyone wishing to engage in SASL can interact, provided you ‘leave your voice at the door’.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept